

PRESS RELEASE- FOR IMMEDIATE RELEASE

IntegraGen – Half year results 2011

Strong progression of the Genomic Services activity. Major strategic breakthrough in diagnostic based projects.

H1 highlights :

- Genomic Services: sales 2.5 m€, + 68% vs H1 2010
- Autism : major strategic progress with the presentation of the results of a study at the Annual Meeting of the Society for Developmental and Behavioral Pediatrics
- Oncology : ongoing development projects, reimbursable funding by OSEO of 1,6 m€ over 3 years

Evry, Wednesday 19th, Oct 2011 - IntegraGen, a leading player in the development and commercialization of molecular diagnostic tests in the field of Autism and Oncology, announces today its financial results for the first half of 2011. H1 accounts have been reviewed by the Board of Directors at a meeting held October 19th, 2011.

MAJOR INDICATORS - In Euro thousands	2011 H1	2010 H1
Revenues	2 498	1 485
Operating Profit	- 1 207	- 1 247
Net profit	- 890	- 1 322
	June 30th 2011	Dec. 31 st ,2010
Cash as of June 30,	4 739	6 018

Bernard Courtieu, Chief Executive Officer, declares:

"IntegraGen has achieved an excellent performance during this half year, with a revenue growth in Services of 68% compared to 2010 first half, as well as major breakthrough in our autism franchise. We are therefore extremely satisfied to be able to demonstrate our ability to develop our products while improving our economic performance in the current environment. Furthermore, the follow up of our research should allow for the publication in 2012 of further major results in autism and to launch new diagnostic tests in the USA.

FINANCIAL ELEMENTS

▪ Profit & Loss statement

Revenues for H1 2011 are 2,498k euros, compared to 1,485k euros for H1 2010, which represents a 68% growth. Revenues were generated by our Genomic Services activities. After taking into account other sources, depreciation variation and provisions, all revenues amount to 2,665k euros, compared to 1,582k euros in H1 2010.

The operational result amounts to a loss of 1,207k euros in the first half of 2011, compared to a loss of 1,247k euros in H1 2010. As expected, operating expenses have increased. This is due in part to the increase in the Services activity of the Company, as well as to new engagements in the Diagnostics activity.

Having taken into account the financial results, exceptional and tax credit related to the research work realized during H1, the net result amounts to a loss of 890k euros, compared to a loss of 1,322k euros in H1 2010.

▪ Balance Sheet

As a reminder, IntegraGen raised a private placement of 6.7 million euros in June 2010.

As of June 30th, net cash amounts to 4,739k euros, compared to 6,018k euros as of December 31st, 2010

ACTIVITY

▪ Genomic Services: 68% growth, led by High Throughput sequencing

With a 68% growth in revenues compared to H1 2010, IntegraGen confirms its superior dynamics and its leadership in genomic services for research entities.

Growth was fueled by the continued demand in high throughput sequencing and by the ability of IntegraGen's laboratories in Evry to deliver superior quality work and to meet the highest quality standards expected by its customers, whether public (State owned) or private. A number of research teams focusing on oncology have worked with IntegraGen's Genomic services team to realize exome sequencing programs (an exome being the coding part of the whole genome), thus positioning IntegraGen as a major contributor to the development of cancer research in France.

During the first half of 2011, IntegraGen achieved more than 80 sequencing or genotyping projects for its clients.

▪ Diagnostic

- **Autism: Presentation to the SDBP of results related to an improved version and initiation of two prospective studies in non familial autism. Confirmation of a marked interest by the North American Pediatric Community into IntegraGen's projects**

At the Annual Meeting of the Society for Behavioral and Developmental Pediatrics (SDBP) held in San Antonio Texas in September 2011, a team of IntegraGen researchers presented the results of a study based on more than 2,000 children from multiplex autism families (families with more than one affected child) from two independent collections. Results of this studies show that it is possible to identify an increased risk of developing autism in children who have older siblings diagnosed with ASD, with a positive

predictive value of above 50% in boys and 25% in girls. The ability to identify children at higher risk will allow the earlier diagnosis of autism in affected children potentially permitting earlier intervention and improved developmental outcomes.

"Identifying tools which aid in the early assessment and diagnosis of children with autism is crucial towards ensuring these children receive treatment as soon as possible since studies have shown that earlier intervention is associated with better outcomes," said Rolanda Maxim, M.D., a developmental pediatrician and Medical Director of the Autism Center at SSM Cardinal Glennon Children's Medical Center in St. Louis, Missouri. *"We are currently conducting a study combining the genetic test IntegraGen has developed with early screening questionnaires to determine if these can be used to improve the early identification of autism in siblings of children with this disorder."*

It is worth noting that pediatricians will be the main prescribers of IntegraGen's test in the field of autism. The presentation of these results at the SBDP meeting highlights the interest amongst pediatric specialists in IntegraGen's autism-related efforts as well as the strong medical need for advances which help to deal with the earlier identification of children at risk of autism.

IntegraGen is also extremely pleased to announce the launch of two separate, prospective clinical trials at The Cleveland Clinic and at Cardinal Glennon Children's Hospital in Saint Louis.

- **Oncology : Implementaiton of the validation programs and financing by OSEO for 1,6 m€ over three years**

IntegraGen oncology projects, initiated in H2 2010 in partnership with teams from INSERM (National Institute for Medical Research, France) , are designed to validate and market genomic biomarkers related to HepatoCellular Carcinoma (liver cancer) and metastatic Colorectal Cancer. These two programmes have been funded by OSEO in April 2011 for a total amount of 1.6 m€ over 3 years, as a zero% interest loan, reimbursable if successfull between 2015 & 2017. This financial support has allowed to speed up the activities and to prepare the patenting of new biomarkers by 2012 and to keep the original development planning.

PERSPECTIVES

IntegraGen expects to keep a steady growth in Genomic Services this year based on the strong demand from R&D centers for leading edge technologies as well as on its unique expertise in France. IntegraGen also notes that because of some major contracts signed in late 2010, the growth of the activity will be slower in H2 than in H1.

Regarding Diagnostic activities, IntegraGen will continue the validation process of its tests in order to launch during H1 2012 a new version of the ARISK™ test for siblings of affected families. This version will pave the way for the launch of a non-familial autism suspicion test. The validation of such test will, in particular, be based on the results of the prospective studies launched in 2011, as well as a number of retrospective studies currently on-going. IntegraGen plans to communicate preliminary results of these studies in early 2013.

ABOUT INTEGRAGEN

IntegraGen (www.integragen.com) is a biotechnology company dedicated to gene discovery with the goal of developing molecular diagnostic products and services that provide clinicians with new tools to personalize diagnosis, treatment, and therapy. IntegraGen, and its wholly owned U.S. subsidiary IntegraGen, Inc., are focused on the prevention and proactive management of complex debilitating diseases, and dedicated to addressing the needs of patients, clinicians, and advocacy groups. IntegraGen's Genetic Services Business, based in Evry, France, also provides state of the art Genotyping Services to the research community. With discovery and intellectual property focused on autism and oncology, IntegraGen's core strategy is to deliver a portfolio of high-value molecular diagnostic products and services that drive personalized healthcare solutions for complex diseases.

CONTACTS



INTEGRAGEN

Bernard Courtieu
CEO
Tel.: +33 (0)1 60 91 09 00

Laurence Riot Lamotte
CFO
contact@integragen.com
Tel.: +33 (0)1 60 91 09 09

NEWCAP.

Investor and media relations

Axelle Vuillermet / Camille McFayden
integragen@newcap.fr
Tel.: +33 (0)1 44 71 94 93